Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Stöhlmacher J, Bernhard H, Gröschel A, Lander T, Probst J, Strack T, Wiegand V, Gnad-Vogt U, Kallen KJ, Hoerr I, von der Muelbe F, Fotin-Mleczek M, Knuth A, Koch SD.

Cancer Immunol Immunother. 2019 May;68(5):799-812. doi: 10.1007/s00262-019-02315-x. Epub 2019 Feb 15.

PMID:
30770959
2.

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.

Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A.

J Immunother Cancer. 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5.

3.

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.

Hong HS, Koch SD, Scheel B, Gnad-Vogt U, Schröder A, Kallen KJ, Wiegand V, Backert L, Kohlbacher O, Hoerr I, Fotin-Mleczek M, Billingsley JM.

Oncoimmunology. 2016 Nov 18;5(12):e1249560. doi: 10.1080/2162402X.2016.1249560. eCollection 2016.

4.

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects.

Ziegler A, Soldner C, Lienenklaus S, Spanier J, Trittel S, Riese P, Kramps T, Weiss S, Heidenreich R, Jasny E, Guzmán CA, Kallen KJ, Fotin-Mleczek M, Kalinke U.

J Immunol. 2017 Feb 15;198(4):1595-1605. doi: 10.4049/jimmunol.1601129. Epub 2017 Jan 11.

5.

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.

Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A.

J Immunother Cancer. 2015 Jun 16;3:26. doi: 10.1186/s40425-015-0068-y. eCollection 2015.

6.

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.

Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheel B, Voss S, Kallen KJ, Fotin-Mleczek M.

Int J Cancer. 2015 Jul 15;137(2):372-84. doi: 10.1002/ijc.29402. Epub 2015 Jan 8.

7.

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.

Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A.

BMC Cancer. 2014 Oct 6;14:748. doi: 10.1186/1471-2407-14-748.

8.

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors.

Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Kowalczyk A, Kallen KJ, Huber SM.

Radiat Oncol. 2014 Aug 15;9:180. doi: 10.1186/1748-717X-9-180.

9.

A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Kallen KJ, Theß A.

Ther Adv Vaccines. 2014 Jan;2(1):10-31. doi: 10.1177/2051013613508729. Review.

10.

The regulatory landscape for actively personalized cancer immunotherapies.

Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U.

Nat Biotechnol. 2013 Oct;31(10):880-2. doi: 10.1038/nbt.2708. No abstract available.

PMID:
24104749
11.

A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.

Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, Baumhof P, Scheel B, Koch SD, Fotin-Mleczek M.

Hum Vaccin Immunother. 2013 Oct;9(10):2263-76. doi: 10.4161/hv.25181. Epub 2013 Jun 4. Review.

12.

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, Kramps T.

Nat Biotechnol. 2012 Dec;30(12):1210-6. doi: 10.1038/nbt.2436. Epub 2012 Nov 25.

PMID:
23159882
13.

Developing mRNA-vaccine technologies.

Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ.

RNA Biol. 2012 Nov;9(11):1319-30. doi: 10.4161/rna.22269. Epub 2012 Oct 12. Review.

14.

NSCLC - immunogenic after all?

Kallen KJ, Gnad-Vogt U.

J Thorac Dis. 2011 Jun;3(2):79-81. doi: 10.3978/j.issn.2072-1439.2011.02.01. No abstract available.

15.

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.

Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, Kallen KJ.

J Gene Med. 2012 Jun;14(6):428-39. doi: 10.1002/jgm.2605.

PMID:
22262664
16.

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ.

J Immunother. 2011 Jan;34(1):1-15. doi: 10.1097/CJI.0b013e3181f7dbe8.

PMID:
21150709
17.

Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.

Mees ST, Toellner S, Marx K, Faendrich F, Kallen KJ, Schroeder J, Haier J, Kahlke V.

J Surg Res. 2009 Dec;157(2):235-42. doi: 10.1016/j.jss.2008.08.035. Epub 2008 Sep 29.

PMID:
19589542
18.

IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier.

Linker RA, Lühder F, Kallen KJ, Lee DH, Engelhardt B, Rose-John S, Gold R.

J Neuroimmunol. 2008 Dec 15;205(1-2):64-72. doi: 10.1016/j.jneuroim.2008.09.007. Epub 2008 Oct 23.

PMID:
18950871
19.

Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.

McCabe C, Bergmann L, Bosanquet N, Ellis M, Enzmann H, von Euler M, Jönsson B, Kallen KJ, Newling D, Nüssler V, Paschen B, de Wilde R, Wilking N, Teale C, Zwierzina H; Biotherapy Development Association.

Ann Oncol. 2009 Mar;20(3):403-12. doi: 10.1093/annonc/mdn603. Epub 2008 Oct 14. Review.

PMID:
18854550
20.

gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes.

Tenhumberg S, Schuster B, Zhu L, Kovaleva M, Scheller J, Kallen KJ, Rose-John S.

Biochem Biophys Res Commun. 2006 Aug 4;346(3):649-57. Epub 2006 Jun 6.

PMID:
16774741

Supplemental Content

Loading ...
Support Center